publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
Edoxaban
Clinical outcomes and anticoagulation therapy in elderly non-valvular atrial fibrillation and heart failure patients
Edoxaban
Risk factors for bleeding events in Japanese patients with advanced lung cancer: Data from the Rising-VTE/NEJ037 Study
Edoxaban
Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial
Edoxaban
Treatment satisfaction and convenience for patients with atrial fibrillation on edoxaban or vitamin K antagonists after transcatheter aortic valve replacement: A post hoc analysis from the ENVISAGE-TAVI AF trial
Edoxaban
Management of edoxaban therapy and clinical outcomes in patients undergoing major or nonmajor surgery: A subanalysis of the EMIT-AF/VTE study
HER3-DXd
HERTHENA-Lung02: Phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI
T-DXd
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: Updated survival results from a phase II trial (DESTINY-Breast01)
Edoxaban
Predictors of all-cause mortality after successful transcatheter aortic valve implantation in patients with atrial fibrillation
T-DXd
Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study
Edoxaban
A multicenter, single-blind, randomized, warfarin-controlled trial of edoxaban in patients with chronic thromboembolic pulmonary hypertension: KABUKI trial